AMW Receives first Notified Body Opinion by TÜV SÜD and Lays the Foundation for Further Approvals of Goserelin in the EU

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has achieved a key milestone in opening new markets within the European Union (EU) and beyond with the final report of the first Notified Body Opinion (NBO) for its goserelin implant.

read more

AMW reports financial results for fiscal 2022 and updates on corporate performance

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today released its financial results for the year ended December 31, 2022. AMW reported record consolidated sales for 2022 of €22.8 million and achieved operating profitability for the first time in the company’s history. The company also reported that Philipp Karbach will assume the position of chief executive officer (CEO) effective June 1, 2023, as Dr. Konstantin Petropoulos has decided to step down as CEO of AMW GmbH effective May 31, 2023, to pursue new opportunities. Philipp Karbach joined AMW in 2016, most recently in his role as Chief Operating Officer (COO) and Chief Financial Officer (CFO).

read more

Brussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau

The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.

read more

Brussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau

The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.

read more